Allergology International

This is a promotion site for the
Allergology International. You can see
the journal contents in Science Direct

Current Issue |
Volume 71, Issue 4
October 2022

Cover of Allergology International

Open Access ISSN: 1323-8930
2021 Impact Factor: 7.478
View More on Journal Insights
© 2022 Journal Citation Reports
© Clarivate Analytics, 2022

Appreciation to Reviewers

The Editors are deeply appreciative of their valuable expertise and contributions to AI. See more

Outstanding Reviewers 2021

About Allergology International

Allergology International is the official journal of the Japanese Society of Allergology and publishes original papers dealing with the etiology, diagnosis and treatment of allergic and related diseases. Papers may include the study of methods of controlling allergic reactions, human and animal models of hypersensitivity and other aspects of basic and applied clinical allergy in its broadest sense.

The Journal aims to encourage the international exchange of results and encourages authors from all countries to submit papers in the following three categories: Original Articles, Review Articles, and Letters to the Editor.

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.

Editor's Choices

Original Article

Editor’s comment: Sublingual immune therapy (SLIT) is a representative disease-modifying treatment for allergic diseases. Hoshino et al. evaluated the outcomes of initiating house dust mite (HDM) SLIT in patients with both asthma and rhinitis whose disease activity was not optimally controlled with dupilumab. They found that the combination therapy of HDM SLIT and dupilumab improved asthma control, increased lung function, and reduced FeNO and wall thickness, suggesting that adding HDM SLIT is beneficial for patients treated with dupilumab.

Original Article

Editor’s comment: Some patients with wheat allergy show clinical cross-reactivity to barley. Kubota et al. examined the clinical cross-reactivity and immunological cross-antigenicity of wheat and barley in patients with wheat allergy to address whether the development of barley allergy in these patients is due to cross-antigenicity between wheat and barley. They found that nine patients who had positive results for oral food challenge (OFC) for barley all became negative on barley-OFC after oral immunotherapy (OIT) for wheat. These findings suggest that barley allergy associated with wheat allergy is caused by cross-reactivity from wheat and that the OIT for wheat is a promising option for barley allergy.

Original Article

Editor’s comment: Some people develop allergic reactions to COVID-19 mRNA vaccines. Polyethylene glycol (PEG) is a potential antigen of these vaccines. Mouri et al. investigated serum PEG-specific IgE/IgG and polysorbate (PS)-specific IgE/IgG in patients who developed immediate allergic reactions to BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) and in some patients, performed skin tests using PEG-2000 and PS-80. They found that PEG is one of the antigens in the allergy to COVID-19 mRNA vaccines and that cross-reactivity between PEG and PS might be involved in allergy to these vaccines, suggesting that PEG-specific IgE and IgG may help predict allergy to these COVID-19 vaccines.

Review Series: Circadian control of immunity and allergy

Invited Review Article

Nakao et al. review recent advances in the circadian control of IgE-dependent and -independent mast cell activation.

Invited Review Article

Ikuta et al. review the recent advances in the roles of glucocorticoids and sex hormones in cells of the innate and adaptive immune systems.

Invited Review Article

Ohdo et al. review the recent advances in chronotherapy (or chronotoxicity). The authors present findings including temporal variabilities in the efficacy of immune checkpoint inhibitors.

To Top